Nuvilex (NASDAQ:PMCB) Trading 5.3% Higher – Here’s Why
Comparing Nuvilex (NASDAQ:PMCB) & Avadel Pharmaceuticals (NASDAQ:AVDL)
PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors
MyMD Pharmaceuticals Secures Strategic Investments
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
PharmaCyte Biotech Announces Final Results of Tender Offer
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan
PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital
PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation
PharmaCyte Biotech Rebukes Iroquois' Commencement of Consent Solicitation
Iroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc.
PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study
PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study
PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study
PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study
PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022
PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022
IROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORS
IROQUOIS CAPITAL ISSUES STATEMENT IN RESPONSE TO RECENT ACTIONS BY THE PHARMACYTE BIOTECH BOARD OF DIRECTORS
PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells
PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells
IROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETING
PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value
PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital's Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value
PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego
PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego
IROQUOIS CAPITAL DELIVERS OPEN LETTER TO PHARMACYTE BIOTECH BOARD OF DIRECTORS
PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value
PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value
PharmaCyte Biotech to Implement $10-Million Share Repurchase Program
PharmaCyte Biotech to Implement $10-Million Share Repurchase Program
PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites
PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites
Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors
PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes
PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes
PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements
PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements
PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial